142 related articles for article (PubMed ID: 37229542)
1. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Kosako H; Yoshida A; Ohtori S; Kawai A; Kondo T
Expert Rev Proteomics; 2023; 20(4-6):109-119. PubMed ID: 37229542
[TBL] [Abstract][Full Text] [Related]
2. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
3. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
González-Muñoz T; Di Giannatale A; García-Silva S; Santos V; Sánchez-Redondo S; Savini C; Graña-Castro O; Blanco-Aparicio C; Fischer S; De Wever O; Creus-Bachiller E; Ortega-Bertran S; Pisapia DJ; Rodríguez-Peralto JL; Fernández-Rodríguez J; Pérez-Portabella CR; Alaggio R; Benassi MS; Pazzaglia L; Scotlandi K; Ratner N; Yohay K; Theuer CP; Peinado H
Clin Cancer Res; 2023 Sep; 29(18):3744-3758. PubMed ID: 37432984
[TBL] [Abstract][Full Text] [Related]
4. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
5. Secretome analysis of human schwann cells derived from malignant peripheral nerve sheath tumor.
Ferdoushi A; Jamaluddin MFB; Li X; Pundavela J; Faulkner S; Hondermarck H
Proteomics; 2022 Jan; 22(1-2):e2100063. PubMed ID: 34648240
[TBL] [Abstract][Full Text] [Related]
6. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
[TBL] [Abstract][Full Text] [Related]
7. Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Ali ES; Krecmerova M; Aguilar JMH; Alt J; Peters DE; Zhao L; Wu Y; Nuha N; Asara JM; Staedtke V; Pratilas CA; Majer P; Rais R; Ben-Sahra I; Slusher BS
Mol Cancer Ther; 2023 Dec; 22(12):1390-1403. PubMed ID: 37616542
[TBL] [Abstract][Full Text] [Related]
8.
Wei M; Fan J; Peng R; Ding X; Xi J; Huang H
Front Biosci (Landmark Ed); 2023 Sep; 28(9):214. PubMed ID: 37796695
[TBL] [Abstract][Full Text] [Related]
9. Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.
Suppiah S; Mansouri S; Mamatjan Y; Liu JC; Bhunia MM; Patil V; Rath P; Mehani B; Heir P; Bunda S; Velez-Reyes GL; Singh O; Ijad N; Pirouzmand N; Dalcourt T; Meng Y; Karimi S; Wei Q; Nassiri F; Pugh TJ; Bader GD; Aldape KD; Largaespada DA; Zadeh G
Nat Commun; 2023 May; 14(1):2696. PubMed ID: 37164978
[TBL] [Abstract][Full Text] [Related]
10. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival.
Black LE; Longo JF; Anderson JC; Carroll SL
Am J Pathol; 2023 Sep; 193(9):1298-1318. PubMed ID: 37328102
[TBL] [Abstract][Full Text] [Related]
12. Advancements in therapeutic approaches for malignant peripheral nerve sheath tumor.
Millesi E; Rechberger JS; Wang H; Mardini S; Spinner RJ; Daniels DJ
Ther Deliv; 2023 Jun; 14(6):385-389. PubMed ID: 37464750
[TBL] [Abstract][Full Text] [Related]
13. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
[TBL] [Abstract][Full Text] [Related]
14. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
[TBL] [Abstract][Full Text] [Related]
15. Malignant peripheral nerve sheath tumor of tongue: a case report.
Liu Y; Wu D; Lun X; Dai W
Hua Xi Kou Qiang Yi Xue Za Zhi; 2023 Jun; 41(3):361-364. PubMed ID: 37277804
[TBL] [Abstract][Full Text] [Related]
16. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
[TBL] [Abstract][Full Text] [Related]
18. Malignant peripheral nerve sheath tumor of the maxilla: Case report and review of the literature with emphasis on its poor prognosis.
Oh KY; Hong SD
Oral Oncol; 2022 Dec; 135():106211. PubMed ID: 36257181
[TBL] [Abstract][Full Text] [Related]
19. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.
Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
Clin Cancer Res; 2011 Dec; 17(24):7563-73. PubMed ID: 22042973
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
